In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer.
The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer.
Caliò
E
E
Oncological Unit, Department of Clinical Medicine, University La Sapienza, I-00197 Rome, Italy.
Seminara
P
P
Aronne
T
T
Sbaffi
E
E
Pagani Guazzugli Bonaiuti
V
V
Gargano
L
L
Franchi
F
F
D000230:Adenocarcinoma / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002452:Cell Count; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000473:pathology*; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005456:Fluorescent Dyes; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D012235:Rhodamines; D014407:Tumor Cells, Cultured
D005456:Fluorescent Dyes; D012235:Rhodamines; C022027:lissamine rhodamine B; D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil